SG10201908048QA - Treatment of Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome - Google Patents
Treatment of Human Immunodeficiency Virus/Acquired Immunodeficiency SyndromeInfo
- Publication number
- SG10201908048QA SG10201908048QA SG10201908048QA SG10201908048QA SG 10201908048Q A SG10201908048Q A SG 10201908048QA SG 10201908048Q A SG10201908048Q A SG 10201908048QA SG 10201908048Q A SG10201908048Q A SG 10201908048QA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- virus
- human immunodeficiency
- immunodeficiency virus
- viral
- Prior art date
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title abstract 4
- 208000030507 AIDS Diseases 0.000 title abstract 2
- 208000031886 HIV Infections Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 4
- 230000003612 virological effect Effects 0.000 abstract 4
- 238000001990 intravenous administration Methods 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 238000010926 purge Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461924936P | 2014-01-08 | 2014-01-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201908048QA true SG10201908048QA (en) | 2019-10-30 |
Family
ID=53494410
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201908048Q SG10201908048QA (en) | 2014-01-08 | 2015-01-08 | Treatment of Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome |
| SG11201605440TA SG11201605440TA (en) | 2014-01-08 | 2015-01-08 | Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201605440TA SG11201605440TA (en) | 2014-01-08 | 2015-01-08 | Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10272143B2 (he) |
| EP (1) | EP3091990B1 (he) |
| JP (1) | JP6557240B2 (he) |
| KR (1) | KR102503400B1 (he) |
| CN (1) | CN105899219B (he) |
| AU (1) | AU2015204770B2 (he) |
| BR (1) | BR112016015736B1 (he) |
| CA (1) | CA2936086C (he) |
| IL (1) | IL246643B (he) |
| PH (1) | PH12016501359A1 (he) |
| SG (2) | SG10201908048QA (he) |
| WO (1) | WO2015105999A1 (he) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150305983A1 (en) * | 2009-11-20 | 2015-10-29 | The University Of Versailles Saint-Quentin-En- Yvelines | Quadruple therapy useful for treating persons afflicted with the human immunodeficiency virus (hiv) |
| US20190069528A1 (en) * | 2016-03-21 | 2019-03-07 | The George Washington University | Engineered human hookworms as a novel biodelivery system for vaccines and biologicals |
| CA3089848A1 (en) * | 2017-09-18 | 2019-03-21 | Cytodyn Inc. | Screening methods for identifying and treating hiv-1 infected patient sub-populations suitable for long term anti-ccr5 agent therapy |
| USD1001795S1 (en) | 2019-10-01 | 2023-10-17 | Microsoft Corporation | Computing device |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020022034A1 (en) * | 1997-09-15 | 2002-02-21 | Julianna Lisziewicz | Therapeutic DNA vaccination |
| HUP0202734A3 (en) * | 1999-05-04 | 2003-11-28 | Schering Corp | Use of pegylated interfron alfa-ccr5 antagonist combination for hiv therapy |
| US6579521B2 (en) | 2000-10-20 | 2003-06-17 | Chiron Corporation | Methods of therapy for HIV infection |
| US7402431B2 (en) | 2004-03-01 | 2008-07-22 | Immunovative Therapies, Ltd. | T-cell therapy formulation |
| US7435592B2 (en) | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
| US20110142887A1 (en) * | 2009-12-15 | 2011-06-16 | Immunovative Therapies Ltd. | Methods and compositions for liquidation of tumors |
| AU2004269379A1 (en) | 2003-08-28 | 2005-03-10 | The Immune Response Corporation | Immunogenic HIV compositions and related methods |
| KR20070019635A (ko) * | 2003-08-28 | 2007-02-15 | 더 임뮨 리스판스 코포레이션 | 면역원성 ｈｉｖ 조성물 및 이와 관련된 방법 |
| HUE028467T2 (en) * | 2004-02-26 | 2016-12-28 | Immunovative Therapies Ltd | A method for producing T-cells for cell therapy |
| EP3202895A1 (en) * | 2004-03-01 | 2017-08-09 | Immunovative Therapies, Ltd. | A composition for use in cell therapy and methods for its preparation |
| US8043619B2 (en) | 2004-10-08 | 2011-10-25 | Yaron Ilan | Methods and uses of leptin in immune modulation |
| US20120128656A1 (en) | 2008-05-02 | 2012-05-24 | Immunovative Therapies, Ltd. | Vaccine compositions and methods |
| US9695397B2 (en) | 2008-10-01 | 2017-07-04 | Immunovative Therapies Ltd. | Th1 vaccination priming for active immunotherapy |
| WO2010051521A1 (en) | 2008-10-31 | 2010-05-06 | Lentigen Corporation | Cell therapy product for the treatment of hiv infection |
| WO2011077100A1 (en) * | 2009-12-24 | 2011-06-30 | Cipla Limited | Antiretroviral composition |
| AU2011231574A1 (en) | 2010-03-26 | 2012-10-11 | Glaxosmithkline Biologicals S.A. | HIV vaccine |
| KR20200063262A (ko) | 2010-04-13 | 2020-06-04 | 이뮤노베이티브 테라피스, 엘티디. | 조절 t 세포들의 저해를 위한 방법 및 조성물 |
| US8686218B2 (en) | 2010-04-14 | 2014-04-01 | The Penn State Research Foundation | Strategies for the transgenic manipulation of filamentous fungi |
-
2015
- 2015-01-08 CN CN201580004106.1A patent/CN105899219B/zh active Active
- 2015-01-08 AU AU2015204770A patent/AU2015204770B2/en active Active
- 2015-01-08 JP JP2016545336A patent/JP6557240B2/ja active Active
- 2015-01-08 US US14/592,701 patent/US10272143B2/en active Active
- 2015-01-08 SG SG10201908048Q patent/SG10201908048QA/en unknown
- 2015-01-08 KR KR1020167021648A patent/KR102503400B1/ko active IP Right Grant
- 2015-01-08 SG SG11201605440TA patent/SG11201605440TA/en unknown
- 2015-01-08 EP EP15735377.2A patent/EP3091990B1/en active Active
- 2015-01-08 WO PCT/US2015/010658 patent/WO2015105999A1/en active Application Filing
- 2015-01-08 CA CA2936086A patent/CA2936086C/en active Active
- 2015-01-08 BR BR112016015736-2A patent/BR112016015736B1/pt active IP Right Grant
-
2016
- 2016-07-06 IL IL246643A patent/IL246643B/he active IP Right Grant
- 2016-07-11 PH PH12016501359A patent/PH12016501359A1/en unknown
-
2018
- 2018-03-15 US US15/922,600 patent/US10729754B2/en active Active
-
2020
- 2020-07-15 US US16/930,079 patent/US20200368334A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016015736B1 (pt) | 2022-01-04 |
| US10272143B2 (en) | 2019-04-30 |
| CA2936086C (en) | 2024-02-27 |
| JP6557240B2 (ja) | 2019-08-07 |
| US20150190488A1 (en) | 2015-07-09 |
| US20200368334A1 (en) | 2020-11-26 |
| CN105899219A (zh) | 2016-08-24 |
| EP3091990B1 (en) | 2021-05-12 |
| KR20160124096A (ko) | 2016-10-26 |
| PH12016501359A1 (en) | 2016-08-22 |
| BR112016015736A2 (he) | 2017-08-08 |
| EP3091990A1 (en) | 2016-11-16 |
| WO2015105999A1 (en) | 2015-07-16 |
| AU2015204770B2 (en) | 2020-07-02 |
| CN105899219B (zh) | 2021-08-13 |
| KR102503400B1 (ko) | 2023-02-23 |
| CA2936086A1 (en) | 2015-07-16 |
| IL246643B (he) | 2020-02-27 |
| US20180200348A1 (en) | 2018-07-19 |
| US10729754B2 (en) | 2020-08-04 |
| JP2017502058A (ja) | 2017-01-19 |
| AU2015204770A1 (en) | 2016-08-18 |
| SG11201605440TA (en) | 2016-08-30 |
| EP3091990A4 (en) | 2017-10-04 |
| IL246643A0 (he) | 2016-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020005187A (es) | Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos. | |
| PH12017500803A1 (en) | Anti-pd-1 antibodies | |
| MX2021004828A (es) | Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
| EA201792092A1 (ru) | Редактирование генов с использованием tat-индуцируемой crispr-эндонуклеазы | |
| MX2019005401A (es) | Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma. | |
| PH12017500965A1 (en) | Myostatin or activin antagonists for the treatment of sarcopenia | |
| JOP20180008A1 (ar) | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b | |
| SG10201811128RA (en) | Ezh2 inhibitors for treating lymphoma | |
| MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| PE20180260A1 (es) | Metodos y kits para tratar la depresion | |
| PH12019501010A1 (en) | Arginase inhibitor combination therapies | |
| MX2017005134A (es) | Tratamiento del cáncer con inmunoestimuladores. | |
| PH12016501359A1 (en) | Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome | |
| EA036102B9 (ru) | Терапевтические средства с углевод-опосредованной адресной доставкой | |
| MX2018005825A (es) | Celulas inmunes modificadas y usos de las mismas. | |
| MX2017011500A (es) | Combinaciones y formulaciones de dosis fijas que comprenden ácido 8-hidroxi-2,2,14,14- tetrametilpentadecanodioico (etc1002) y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| EA202190927A1 (ru) | Иммуноаблативные виды терапии | |
| WO2015130554A3 (en) | Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith | |
| BR112017021700A2 (pt) | composições terapêuticas e métodos de uso para o tratamento do câncer | |
| BR112016028726A2 (pt) | métodos de tratamento de um paciente diagnosticado com diabetes tipo 1, métodos de redução, supressão, atenuação ou inibição de um ou mais sintomas associados com t1d, e métodos de tratamento de um paciente que está em risco de t1d | |
| MX2021001612A (es) | Compuestos utiles en terapia del vih. | |
| MX2018002816A (es) | Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t. | |
| MX2017015532A (es) | Terapia de combinacion pac-1. | |
| MX2020013621A (es) | Composiciones y metodos de tratamiento de vih. | |
| WO2017181099A8 (en) | Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith |